According to a new report, published by KBV research, The Global Age Related Macular Degeneration (AMD) Market size is expected to reach $13.9 billion by 2030, rising at a market growth of 5.4% CAGR during the forecast period.
The Ranibizumab segment would witness a CAGR of 5.7% during (2023 - 2030). A recombinant humanized monoclonal antibody is called ranibizumab. The treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein blockage, diabetic macular swelling, diabetic retinal degeneration, and myopic choroidal neovascularization is recommended with the antibody injection for intravitreal usage.
The Wet segment is leading the Global Age Related Macular Degeneration (AMD) Market by Disease Type in 2022; thereby, achieving a market value of $11.9 billion by 2030. The development of regular blood vessels beneath the layer of the retina begins with wet age-related macular degeneration. Since AMD is the most common cause of substantial loss of vision in people over 50, the growing geriatric population worldwide is creating high demand in the wet AMD segment.
The Hospital Pharmacy segment is registering a CAGR of 5 % during the forecast period. The rise in age-related macular degeneration (AMD) prevalence and hospitalization for treatment are responsible for this dominance. Most patients are treated in hospitals using various drugs administered intravenously under the care of approved medications, including Lucentis, Eylea, and Beovu.
The North America region dominated the Global Age Related Macular Degeneration (AMD) Market by Region in 2022; thereby, achieving a market value of $6.3 billion by 2030. The Europe market is poised to grow at a CAGR of 5% during (2023 - 2030). Additionally, The Asia Pacific market would witness a CAGR of 6.4% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/age-related-macular-degeneration-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Biogen, Inc., Bayer AG, Apellis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Ionis Pharmaceuticals, Inc., Novartis AG, Sanofi S.A., Coherus Biosciences, Inc. and Bausch Health Companies, Inc.
By Drug Type
By Disease Type
By Distribution Channel
By Geography
Companies Profiled
Unique Offerings 
